In three practice guidelines from ASCO, experts provide evidence-based recommendations that address overarching clinical questions for the management of patients with pancreatic cancer. These guidelines offer improved strategies for interdisciplinary patient management and highlight the need for further research in several areas.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Khorana, A. A. et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 2541–2556 (2016).
Balaban, E. P. et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 2654–2668 (2016).
Sohal, D. P. et al. Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2016.67.1412 (2016).
Bockhorn, M. et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155, 977–988 (2014).
Chandrasegaram, M. D. et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br. J. Surg. 102, 1459–1472 (2015).
Strobel, O. et al. Pancreatic cancer surgery: the new R-status counts. Ann. Surg. http://dx.doi.org/10.1097/SLA.0000000000001731 (2016).
Neoptolemos, J. P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073–1081 (2010).
Neoptolemos, J. P. et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J. Clin. Oncol. Abstr. 34, aLBA4006 (2016).
Strobel, O. et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann. Surg. 261, 961–969 (2015).
Allen, P. J. et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann. Surg. http://dx.doi.org/10.1097/SLA.0000000000001763 (2016).
Suker, M. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 17, 801–810 (2016).
Hackert, T. et al. Locally advanced pancreatic cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients. Ann. Surg. http://dx.doi.org/10.1097/SLA.0000000000001850 (2016).
The authors declare no competing financial interests.
About this article
Cite this article
Strobel, O., Büchler, M. Clinical practice guidelines — what is the evidence?. Nat Rev Clin Oncol 13, 593–594 (2016). https://doi.org/10.1038/nrclinonc.2016.127
South Russian Journal of Cancer (2020)
The efficacy and safety of the open approach irreversible electroporation in the treatment of pancreatic cancer: A systematic review
European Journal of Surgical Oncology (2020)
Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
American Journal of Clinical Oncology (2020)
Journal of Clinical Medicine (2019)
Nature Reviews Clinical Oncology (2019)